- BMO Capital Markets initiated coverage on Legend Biotech Corporation LEGN with a price target of $77, and an Outperform rating.
- The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy.
- Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
- Though the analyst expects a gradual increase in sales due to manufacturing limitations, in the long term, he sees a blockbuster opportunity for Carvykti as the leader in multiple myeloma CAR T therapies with peak sales of around $5.5 billion.
- Legend and its collaborator Janssen, a unit of Johnson & Johnson JNJ, are working on expanding Carvykti's addressable population through approvals in earlier lines and Japan & China that will bolster additional growth.
- The analyst also notes upcoming data readouts from earlier-line therapies that can drive short-term upside.
- Price Action: LEGN shares are up 6.84% at $45.90 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorBiotechLarge CapNewsHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
